AgomAb Therapeutics NV (AGMB) stock
Close on Nov 12, 2026Market cap $159.00KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- €142.55K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -€62.55M
- EPS, diluted
- -143.22 EUR
Trading
- Previous close
- $6.99
- Open
- $6.90
- Day's range
- $6.19 – $6.98
- Volume
- 1,517,921
- Average volume (20 days)
- 280,238
- RSI (14 days)
- 29.1
- Volatility (1 year)
- 90.9%
- Relative volume
- 10.14×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AGMB | S&P 500 | Difference | AGMB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -30.0% | -2.7% | −27.3 pts | ||
| 3 months | -54.9% | -1.7% | −53.2 pts | ||
| Year to date | +63500.0% | +11.9% | +63488.1 pts | ||
| 1 year | +63500.0% | +12.0% | +63488.0 pts | ||
| 3 years | +63500.0% | +78.2% | +63421.8 pts | +760.0% | +21.2% |
| 5 years | +63500.0% | +73.2% | +63426.8 pts | +263.7% | +11.6% |
| 10 years | +63500.0% | +309.6% | +63190.4 pts | +90.7% | +15.1% |
Four years at a glance
Fiscal years 2022 to 2025, EUR
Operating income
Net income
EPS, diluted
Press releases
Releases AgomAb Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About AgomAb Therapeutics
Biological Products, (No Diagnostic Substances)
AgomAb Therapeutics NV is a biotechnology company focused on advancing therapeutic research programs and developing specialized medicinal assets. The enterprise engages in proprietary scientific evaluation, pipeline innovation, and licensing arrangements to target serious medical conditions. Its operations and related transactions primarily interface with clinical collaborators, institutional healthcare entities, and specialized biotechnology partners across the life sciences ecosystem.
Company profile, executives and historyAgomAb Therapeutics stock: common questions
What is AgomAb Therapeutics's stock price?
AGMB closed at $6.36 on Nov 12, 2026, down 9.01% on the day.
What is AgomAb Therapeutics's market cap?
AgomAb Therapeutics was worth $159.00K at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AGMB's P/E ratio?
AgomAb Therapeutics lost money over fiscal 2025 (diluted EPS -143.22 EUR), so it has no meaningful P/E ratio.
Does AgomAb Therapeutics pay a dividend?
No. AgomAb Therapeutics has not paid a cash dividend over the last twelve months.
How has AGMB stock performed over the past year?
Including dividends, AGMB returned +63500.0% over the past year, against +12.0% for the S&P 500.
Who are AgomAb Therapeutics's competitors?
Companies most similar to AgomAb Therapeutics by business, industry and size include IMTX, AGEN, ELOX, AMGN, SGMOQ.
See a number that looks wrong?